ArticleEJNMMI physics2021
Tissue dose estimation after extravasation of
Article in EJNMMI physics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07174089 (New AI-based Technologies for Even Safer and More Precise Nuclear Medicine), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
New AI-based Technologies for Even Safer and More Precise Nuclear Medicine
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Gravity versus pump-driven infusion in targeted radionuclide therapy: a model-based dosimetric evaluation of extravasation.EJNMMI physics · 2026Article
- Real-time detection of extravasation events of diagnostic and therapeutic radiopharmaceuticals in oncology.PloS one · 2026Article
- Extravasation Frequency of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Safety injections of nuclear medicine radiotracers: towards a new modality for a real-time detection of extravasation events andEJNMMI physics · 2023Article
- Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals.Pharmaceutics · 2023Review
- Extravasation of Diagnostic Radiopharmaceuticals: A Wolf in Sheep's Clothing?Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- The decision to reimage following extravasation in diagnostic nuclear medicine.Frontiers in nuclear medicine · 2023Article
- Radiopharmaceutical extravasations: a twenty year mini-review.Frontiers in nuclear medicine · 2023Review
- 177Lu-DOTA-0-Tyr3-octreotate infusion modeling for real-time detection and characterization of extravasation during PRRT.EJNMMI physics · 2022Article
- Swelling of the Right Arm During a Nuclear Medicine Therapy for Metastatic Pheochromocytoma.AACE clinical case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtravasation of radiopharmaceuticals used for vectorized internal radiotherapy can lead to severe tissue damage (van der Pol et al., Eur J Nucl Med Mol Imaging 44:1234-1243, 2017). Clinical management of these extravasations requires the preliminary estimation of the dose distribution in the extravasation area. Data are scarce regarding the dose estimation in the literature. This work presents a methodology for estimating the dose distribution after an extravasation occurred in September 2017, in the arm of a patient during a 7.4-GBq infusion of Lutathera ® (AAA).
methodsA local quantification procedure initially developed for renal dosimetry was used. A calibration factor was determined and verified by phantom study. Extravasation volume of interest and its variation in time were determined using 4 whole body (WB) planar acquisitions performed at 2 h (T
resultsVolumes estimated using 3D threshold were V
conclusionsRapid local dose estimation was permitted thanks to knowledge of the calibration factor determined previous to accidental extravasation. Lutathera® lymphatic drainage was quick in the arm (T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.